Therefore, anti-TNF biologics and/or adiponectin analogs or medications that increase endogenous adiponectin may be investigated combined with ICIs in the treatment of NAFLD-associated HCC. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.